# Radiation Combined With BIspecific T-Cell Engager in DLL3 Expressing Tumors

Source: https://onco.cc/trials/nct06814496/  
OnCo record `nct06814496` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 1/2 trial of tarlatamab in lung cancer, run by University of Arizona, now recruiting.

## Summary

Radiation Combined With BIspecific T-Cell Engager in DLL3 Expressing Tumors is a phase 1/2, interventional study registered as NCT06814496 by University of Arizona, with a registry enrolment figure of 30 participants, started 2025-09-08 and due to reach its primary completion in 2030-05. Interventions recorded: Tarlatamab; Concurrent Radiation Therapy; Sequential Radiation therapy. Conditions listed: Melanoma; Medullary Thyroid Cancer; Sinonasal Undifferentiated Carcinoma; Esthesioneuroblastoma; Bladder Cancer; Testicular Cancer; Glioblastoma Multiforme; Cervical Cancer; Large Cell Neuroendocrine Carcinoma of the Lung; Non Small Cell Lung Cancer;. Primary outcome: Percentage of participants experiencing dose limiting toxicities (DLT) attributed to radiation or combination of radiation and tarlatamab.. Lung eligibility wording from the registry: "SCLC". Sites: United States. No results are recorded here; the registry entry is the source.

## Fields

- Kind: Trial
- Status: recruiting
- Last checked: 2026-09-25
- Also known as: RABBIT
- Tags: ctgov-ingest; lung-deep-dive
- Registry id: NCT06814496
- Phase: 1/2
- Setting: RAdiation comBined With BIspecific T-Cell Engager in DLL3 Expressing Tumors (RABBIT) Study: A Phase I/II Study of AMG757 / Tarlatamab and Concurrent Radiation Therapy in Tumors With High Prevalence of DLL3
- Sponsor: University of Arizona
- Enrolled: 30

## Sources

- ClinicalTrials.gov NCT06814496: https://clinicaltrials.gov/study/NCT06814496

## Connected records

- cancers: [Non-small-cell lung cancer](https://onco.cc/cancers/nsclc/)
- technologies: [Bispecific antibodies](https://onco.cc/technologies/bispecific-antibody/), [IMRT / IGRT (modern external beam)](https://onco.cc/technologies/imrt-igrt/), [T-cell engagers (bispecific)](https://onco.cc/technologies/t-cell-engager/)
- drugs: [Tarlatamab](https://onco.cc/drugs/tarlatamab/)
- companies: [Amgen](https://onco.cc/companies/amgen/)
- terms: [Lung cancer trials open today (registry snapshot)](https://onco.cc/terms/lung-trials-open-today/)

---
JSON: https://onco.cc/api/v1/entities/nct06814496.json